Samuel Ejadi
Impact in
- Otorhinolaryngology top 2%
- Head and Neck Cancer Studies
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 18
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 4
-
- Prostate Cancer Treatment and Research 5
- Lung Cancer Treatments and Mutations 3
- Co-authors
- Sanatan Saraf (5 shared papers)Roger B. Cohen (4 shared papers)Sarina A. Piha‐Paul (6 shared papers)Aaron R. Hansen (4 shared papers)Emilie M.J. van Brummelen (5 shared papers)John M. Wallmark (4 shared papers)Patrick A. Ott (2 shared papers)Pradeep Thanigaimani (3 shared papers)
- Journals
- Journal of Clinical Oncology (11 papers)Annals of Oncology (6 papers)European Journal of Cancer (5 papers)Scientific Reports (1 paper)PLoS ONE (1 paper)
- Partner nations
- United StatesSouth KoreaCanada
In The Last Decade
Samuel Ejadi
32 papers receiving 1.6k citations
Samuel Ejadi's Hit Papers
Peers
Comparison fields: 5 of 79
- Otorhinolaryngology 144
- Oncology 841
- Immunology 375
- Cancer Research 219
- Pulmonary and Respiratory Medicine 386
Countries citing papers authored by Samuel Ejadi
This map shows the geographic impact of Samuel Ejadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Ejadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Ejadi more than expected).
Fields of papers citing papers by Samuel Ejadi
This network shows the impact of papers produced by Samuel Ejadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Ejadi. The network helps show where Samuel Ejadi may publish in the future.
Co-authors
The 25 scholars most cited alongside Samuel Ejadi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 311 | |
| 2 | Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study Hit paper breakdown → | 2018 | 265 |
| 3 | 2017 | 224 | |
| 4 | 2017 | 166 | |
| 5 | 2008 | 90 | |
| 6 | 1988 | 83 | |
| 7 | 2015 | 82 | |
| 8 | 2008 | 77 | |
| 9 | 2019 | 60 | |
| 10 | 2016 | 46 | |
| 11 | 2016 | 36 | |
| 12 | 2016 | 29 | |
| 13 | 2020 | 25 | |
| 14 | 2019 | 22 | |
| 15 | 2015 | 18 | |
| 16 | 2018 | 16 | |
| 17 | 2015 | 15 | |
| 18 | 2015 | 13 | |
| 19 | 2015 | 12 | |
| 20 | 2014 | 12 |
About Samuel Ejadi
Samuel Ejadi is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology and Surgery, having authored 34 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (6 papers), Prostate Cancer Treatment and Research (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Colorectal and Anal Carcinomas (3 papers), Lung Cancer Treatments and Mutations (3 papers), Head and Neck Cancer Studies (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Otorhinolaryngology (144 citations), Oncology (841 citations), Immunology (375 citations), Cancer Research (219 citations) and Pulmonary and Respiratory Medicine (386 citations). Samuel Ejadi has collaborated with scholars based in United States, South Korea and Canada. Frequent co-authors include Sanatan Saraf, Roger B. Cohen, Sarina A. Piha‐Paul, Aaron R. Hansen, Emilie M.J. van Brummelen, John M. Wallmark, Patrick A. Ott, Pradeep Thanigaimani, Caroline Even and Alain P. Algazi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Scientific Reports and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.